Arjun Balar
0000-0003-3949-5656
78 papers found
Refreshing results…
Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA
Integrating Cd8 and Cd4 Effector Neo-epitope Content with Regulatory T Cell Epitope Exclusion is a Superior Prognostic Biomarker for Bladder Cancer Patient Compared to Their Tumor Mutation Burden
BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma
Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-risk Non-muscle-invasive Bladder Cancer (nmibc) Unresponsive to Bacillus Calmette-guerin (bcg)
PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials
Single cell analysis of urothelial carcinoma (UC) liver metastases identifies epithelial-mesenchymal transition (EMT) as a potential mechanism of resistance to immunotherapy.
Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study
Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).
NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?
Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).
Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma
Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin‐Based Chemotherapy for Muscle‐Invasive Bladder Cancer
Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience
Outcomes with First-line Pd-1/pd-l1 Inhibition in Advanced Urothelial Cancer (uc): a Single Institution Experience
Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial
Missing publications? Search for publications with a matching author name.